PEPTONIC MEDICAL Cash Flow Conversion Efficiency
PEPTONIC MEDICAL cash flow conversion efficiency. Based on the latest financial reports, PEPTONIC MEDICAL (28L) has a cash flow conversion efficiency ratio of -0.112x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.48 Million ≈ $-6.41 Million USD) by net assets (€49.17 Million ≈ $57.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PEPTONIC MEDICAL (2021–2025)
Cash flow conversion efficiency of PEPTONIC MEDICAL from 2021 to 2025. This chart illustrates how PEPTONIC MEDICAL's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PEPTONIC MEDICAL (28L) share price today for real-time trading data and today's change.
PEPTONIC MEDICAL Cash Flow Conversion Ratio Explained
PEPTONIC MEDICAL cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PEPTONIC MEDICAL Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PEPTONIC MEDICAL ranked by their cash flow conversion efficiency. Also see how much is PEPTONIC MEDICAL worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENEFI Energiahatekonysagi Nyrt
BUD:ENEFI
|
-0.013x |
|
Kolon Global Corp
KO:003075
|
0.132x |
|
Tambourah Metals Ltd
AU:TMB
|
-0.007x |
|
SVP GLOBAL TEXTILES LIMITED
NSE:SVPGLOB
|
-0.001x |
|
CARTIER SILVER CORP
F:2CI0
|
N/A |
|
Computer Forms (Malaysia) Bhd
KLSE:8044
|
-0.108x |
|
Tenon Medical Inc
NASDAQ:TNON
|
1.582x |
|
Epsilon Healthcare Ltd
AU:EPN
|
0.265x |
Annual Cash Flow Conversion Efficiency for PEPTONIC MEDICAL (2021–2025)
The table below shows the annual cash flow conversion efficiency of PEPTONIC MEDICAL from 2021 to 2025. Review PEPTONIC MEDICAL free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €38.24 Million ≈ $44.71 Million |
€-20.50 Million ≈ $-23.96 Million |
-0.536x | +30.72% |
| 2024-12-31 | €48.55 Million ≈ $56.76 Million |
€-37.55 Million ≈ $-43.91 Million |
-0.774x | -72.34% |
| 2023-12-31 | €75.32 Million ≈ $88.06 Million |
€-33.81 Million ≈ $-39.53 Million |
-0.449x | +47.44% |
| 2022-12-31 | €47.09 Million ≈ $55.06 Million |
€-40.22 Million ≈ $-47.02 Million |
-0.854x | -12.45% |
| 2021-12-31 | €53.12 Million ≈ $62.10 Million |
€-40.34 Million ≈ $-47.16 Million |
-0.759x | -- |
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopau… Read more